{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.80","upperLimit":"0.87","value":"0.84"},{"groupId":"OG001","lowerLimit":"0.82","upperLimit":"0.91","value":"0.87"}]}],"title":"2 Months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.70","upperLimit":"0.78","value":"0.74"},{"groupId":"OG001","lowerLimit":"0.73","upperLimit":"0.85","value":"0.80"}]}],"title":"4 Months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.58","upperLimit":"0.69","value":"0.64"},{"groupId":"OG001","lowerLimit":"0.57","upperLimit":"0.75","value":"0.67"}]}],"title":"6 Months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.50","upperLimit":"0.63","value":"0.57"},{"groupId":"OG001","lowerLimit":"0.32","upperLimit":"0.61","value":"0.47"}]}],"title":"9 Months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"485"},{"groupId":"OG001","value":"239"}],"units":"Participants"}],"description":"The ECOG PS (Eastern Cooperative Oncology Group Performance Scale) is a standard criteria for measuring how treatment of cancer impacts level of functioning in terms of the ability to care for oneself, daily activity, \\& physical ability (walking, working, etc.). Scale score ranges:0 to 5, 5 being the worst. Scale index: 0: Fully active, able to carry on all pre-disease performance without restriction. 1: Restricted in physically strenuous activity but ambulatory \\& able to carry out work of a light or sedentary nature. 2: Ambulatory \\& capable of all self-care but unable to carry out any work activities. Up \\& about more than 50% of waking hours. 3: Capable of only limited self-care, confined to bed or chair more than 50% of waking hours. 4 - Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair. 5 - Dead. A deterioration of ECOG is an increase of 1 of the ECOG PS without improvement back to initial level at a subsequent time of measurement.","dispersionType":"95% Confidence Interval","groups":[{"description":"Everolimus 10 mg daily in combination with exemestane 25 mg daily","id":"OG000","title":"Everolimus + Exemestane"},{"description":"Placebo of everolimus in combination with exemestane 25 mg daily","id":"OG001","title":"Placebo + Exemestane"}],"paramType":"NUMBER","populationDescription":"All randomized patients were included in the Full Analysis Set.","reportingStatus":"POSTED","timeFrame":"2, 4, 6, 9 months","title":"Proportion of Patients With no Deterioration of Eastern Cooperative Oncology Group Performance Status (ECOG PS) Using Kaplan-Meier","type":"SECONDARY","unitOfMeasure":"Proportion of patients"}